<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266405</url>
  </required_header>
  <id_info>
    <org_study_id>20-003-B</org_study_id>
    <nct_id>NCT04266405</nct_id>
  </id_info>
  <brief_title>Efficacy Testing of Collagen and Zhuyin Drinks</brief_title>
  <official_title>Efficacy Testing of Collagen and Zhuyin Drinks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCI Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TCI Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess collagen and zhuyin drink on skin &amp; body condition improvement
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 9, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The change of skin moisture</measure>
    <time_frame>Change from Baseline skin moisture at 4 weeks</time_frame>
    <description>Corneometer速 CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer速 units 0-120</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin wrinkles</measure>
    <time_frame>Change from Baseline skin wrinkles at 4 weeks</time_frame>
    <description>VISIA Complexion Analysis System was utilized to measure wrinkles. Units: arbitrary units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin collagen density</measure>
    <time_frame>Change from Baseline skin collagen density at 4 weeks</time_frame>
    <description>DermaLab速 USB - 20 MHz High Freq. Ultrasound probe was utilized to scan and analyze skin collagen density. Units:Intensity score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of TEWL</measure>
    <time_frame>Change from Baseline TEWL at 4 weeks</time_frame>
    <description>Tewameter速 TM 300 was utilized to measure TEWL. Units: g/h/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin brightness</measure>
    <time_frame>Change from Baseline skin brightness at 4 weeks</time_frame>
    <description>Glossymeter GL 200 was utilized to measure skin brightness. Units: arbitrary units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of interleukin-6</measure>
    <time_frame>Change from Baseline skin brightness at 4 weeks</time_frame>
    <description>Venous blood was sampled to measure concentrations of interleukin-6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of interleukin-8</measure>
    <time_frame>Change from Baseline skin brightness at 4 weeks</time_frame>
    <description>Venous blood was sampled to measure concentrations of interleukin-8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of Tumor necrosis factor</measure>
    <time_frame>Change from Baseline skin brightness at 4 weeks</time_frame>
    <description>Venous blood was sampled to measure concentrations of Tumor necrosis factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of Matrix metalloproteinase-1</measure>
    <time_frame>Change from Baseline skin brightness at 4 weeks</time_frame>
    <description>Venous blood was sampled to measure concentrations of Matrix metalloproteinase-1 .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of metallopeptidase inhibitor 1</measure>
    <time_frame>Change from Baseline skin brightness at 4 weeks</time_frame>
    <description>Venous blood was sampled to measure concentrations of metallopeptidase inhibitor 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of skin texture</measure>
    <time_frame>Change from Baseline skin texture at 4 weeks</time_frame>
    <description>VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of skin pores</measure>
    <time_frame>Change from Baseline skin pores at 4 weeks</time_frame>
    <description>VISIA Complexion Analysis System was utilized to measure skin pores. Units: arbitrary units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of skin spots</measure>
    <time_frame>Change from Baseline skin spots at 4 weeks</time_frame>
    <description>VISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of red areas</measure>
    <time_frame>Change from Baseline red areas at 4 weeks</time_frame>
    <description>VISIA Complexion Analysis System was utilized to measure red areas. Units: arbitrary units</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Skin Condition</condition>
  <arm_group>
    <arm_group_label>Placebo drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Collagen and Zhuyin Drinks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo drink</intervention_name>
    <description>consume 1 bottle (50 mL) per day for 28 days</description>
    <arm_group_label>Placebo drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Collagen Cubilose Drink</intervention_name>
    <description>consume 1 bottle (50 mL) per day for 28 days</description>
    <arm_group_label>Collagen and Zhuyin Drinks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged above 20 years old

        Exclusion Criteria:

          -  Subject who is not willing to participate in this study.

          -  Patients with diseases of the skin, heart, liver, kidney, endocrine and other organs
             and patients with mental illness (according to medical history).

          -  Subjects who have known cosmetic, drug or food allergies, difficulty in digestive
             tract absorption or disorder.

          -  Female who is pregnant or nursing or planning to become pregnant during the course of
             the study.

          -  Received facial laser therapy, chemical peeling or UV overexposure in the past 4
             weeks.

          -  Vegetarian

          -  Subjects who have large spots (area &gt;3 square centimeter) or abnormal acne.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Hua Liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chia-Hua Liang</last_name>
    <phone>+886-06-2661911</phone>
    <phone_ext>2441</phone_ext>
    <email>tinna_ling@mail.cnu.edu.tw</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

